T1	Participants 44 68	migraine in adolescents:
T2	Participants 202 225	adolescent migraineurs.
T3	Participants 286 371	Patients aged 12 to 17 years received rizatriptan 5 mg (n = 149) or placebo (n = 147)
T4	Participants 1846 1897	adolescents for the treatment of a migraine attack.
